Oxford BioMedica plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oxford BioMedica plc
Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
Keeping Track: Kadmon Chooses RTOR For Belumosudil; NDAs For Novel Imaging Agents And Liquid Anticonvulsants
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Oxxon Therapeutics Limited